PARSAIK and KHOSH-CHASHM: Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, TX SINGH: Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, ND, and Department of Neurology, Mayo Clinic, Rochester, MN MASCARENHAS: Health Care Management, London Training College, London, UK.
1 paper in the library · 42 citations · publishing 2015
A single intravenous dose of ketamine significantly reduces symptoms of treatment-resistant bipolar depression compared with placebo, with maximum improvement observed 40 minutes after infusion. The meta-analysis of three randomized controlled trials (69 subjects) showed a large effect (standardized mean difference -1.01). No serious side effects occurred, and side effects were similar between ketamine and placebo. Individual studies also reported reduced anhedonia and suicidal ideation after ketamine therapy.